Nephromag (Buffered Phosphate Solution | Mertiatide)

Mertiatide provides phosphate ions in a buffered medium, quickly raising serum phosphate while maintaining pH stability. The phosphate serves as a substrate for cellular metabolism and bone health, and the buffering component helps prevent significant shifts in blood acidity during infusion.

The dose of Nephromag is individualized by the prescribing clinician based on the patient’s serum phosphate level, renal function, and clinical condition. Healthcare professionals determine the appropriate volume and infusion rate for each case.

Safety of Nephromag in pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Nephromag, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Nephromag offers a buffered formulation that helps maintain pH stability during infusion, which can reduce the risk of acid‑base disturbances compared with non‑buffered phosphate solutions. Its intravenous route allows rapid correction of phosphate deficits, making it suitable for acute settings such as dialysis or intensive care.

Nephromag should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, inspect for particulate matter and ensure the product is at the appropriate temperature for infusion.

Nephromag is administered intravenously, typically via a controlled infusion pump. The infusion rate and total volume are set by the treating physician according to the patient’s laboratory values and clinical response, with regular monitoring of serum phosphate and calcium.

Serious risks include severe hyperphosphatemia leading to calcium‑phosphate precipitation, anaphylactic reactions, metabolic acidosis, and worsening renal function. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Nephromag is contraindicated in patients with existing hyperphosphatemia, uncontrolled calcium overload, or known hypersensitivity to any component of the formulation. Clinicians should also exercise caution in patients with severe renal failure or those receiving high doses of calcium or vitamin D.